Iovance Biotherapeutics
Iovance Biotherapeutics is advancing cancer treatment by utilizing the human immune system's ability to target diverse cancer cells through investigational TIL therapies, with clinical trials in various solid tumors and blood cancers.
Company History
Iovance Biotherapeutics has established itself as a key player in the biotechnology sector by focusing on innovative cancer treatments. The company is pioneering the use of tumor infiltrating lymphocytes (TIL) to harness the body’s immune system to combat diverse cancer types. This approach has put Iovance at the forefront of advancements in T-cell-based immunotherapy. With multiple clinical trials underway and a state-of-the-art facility in Philadelphia, PA, Iovance continues to push the boundaries of cancer treatment.
Therapies and Clinical Trials
Iovance Biotherapeutics is actively investigating the use of TIL therapies in advanced solid tumors, including melanoma, non-small cell lung cancer (NSCLC), cervical cancer, and head and neck cancer. The company's notable clinical trials include the Phase 3 TILVANCE-301 for unresectable or metastatic melanoma, and the Phase 2 IOV-LUN-202 for recurrent or metastatic NSCLC. Iovance is also exploring peripheral blood lymphocyte (PBL) therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). These investigational therapies are part of Iovance's comprehensive effort to offer new treatment options for cancer patients.
Cell Therapy Technology
Iovance Biotherapeutics utilizes advanced T-cell-based immunotherapy technology platforms for treating various cancer types. The company's proprietary Gen 2 and Gen 3 technologies enhance manufacturing and logistical efficiencies, reducing production time and improving treatment delivery. Gen 3, for instance, shortens the manufacturing period to 16 days. The TIL therapy process involves harvesting TIL from patients, amplifying and reinvigorating them, and then re-infusing them as a one-time treatment after a preparative regimen. These innovations position Iovance as a leader in the development of next-generation cancer therapies.
Iovance Cell Therapy Center (iCTC)
Located in Philadelphia, PA, the Iovance Cell Therapy Center (iCTC) is a state-of-the-art, 136,000-square-foot facility designed for high-volume manufacturing and flexibility. Utilizing proprietary good manufacturing practices (GMP), the iCTC is equipped to meet the treatment demands of thousands of patients annually. Strategically located in a biotechnology hub, the facility supports logistics and distribution of TIL therapies across North America, Europe, and other markets. This enables Iovance to efficiently manage the production and delivery of its cell-based therapies on a global scale.
Research Collaborations and Partnerships
Iovance Biotherapeutics has established strategic partnerships to advance its TIL therapies. A significant collaboration is with the National Institutes of Health/National Cancer Institute under a Cooperative Research and Development Agreement (CRADA) for TIL therapy development. Additionally, Iovance has a worldwide license agreement with Cellectis to use TALEN® technologies for modifying TIL for various cancers. These partnerships enhance Iovance's research capabilities and broaden the scope of its innovative cancer treatment solutions.